SCHEMBL25472502

SCHEMBL25472502

C[C@@H](N[S@@+]([O-])C(C)(C)C)c1cccc(C(F)(F)CCC2CN(C(=O)OC(C)(C)C)C2)c1F

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 1/20 0.37
▸ KAT6A Q92794 1/20 0.36
▸ KAT5 Q92993 1/20 0.36
▸ GPR119 Q8TDV5 5/20 0.35
▸ EPHX2 P34913 1/20 0.34
▸ ALOX5AP P20292 1/20 0.34
▸ FEN1 P39748 1/20 0.34
▸ SOS1 Q07889 3/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ TACR1 P25103 1/20 0.33
▸ USP30 Q70CQ3 1/20 0.33
▸ PLK1 P53350 1/20 0.33
▸ ACKR3 P25106 1/20 0.33
▸ RORC P51449 1/20 0.33
▸ KAT7 O95251 1/20 0.33
▸ KAT8 Q9H7Z6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29898019 1.00 NAMPT (0.37) NAMPTKAT6AKAT5GPR119EPHX2
SCHEMBL26610940 0.91 NAMPT (0.38) NAMPTKAT6AKAT5GPR119ALOX5AP
SCHEMBL26610938 0.91 NAMPT (0.38) NAMPTKAT6AKAT5GPR119ALOX5AP
SCHEMBL26610939 0.91 NAMPT (0.38) NAMPTKAT6AKAT5GPR119ALOX5AP
SCHEMBL25094741 0.84 NAMPT (0.39) NAMPTKAT6AKAT5GPR119ALOX5AP
SCHEMBL26728704 0.83 NAMPT (0.38) NAMPTKAT6AKAT5GPR119EPHX2
SCHEMBL26696289 0.83 NAMPT (0.38) NAMPTKAT6AKAT5GPR119EPHX2
SCHEMBL27138352 0.83 NAMPT (0.38) NAMPTKAT6AKAT5GPR119EPHX2
SCHEMBL23326529 0.78 GPR119 (0.36) GPR119SOS1USP30
SCHEMBL23326528 0.78 GPR119 (0.36) GPR119SOS1USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KRAS, NRAS, BRAF NAMPT 748/4885KAT6A 4393/4885KAT5 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback